← Back to Clinical Trials
Recruiting NCT07474376

NCT07474376 Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07474376
Status Recruiting
Phase
Sponsor Emory University
Condition Diabetes Mellitus, Type 2
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-06
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Fabla Mobile App

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-06 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate whether an audio diary mobile application (Fabla-diabetesMM) is feasible to use and may support self-management in older adults with type 1 or 2 diabetes and multimorbidity. The main questions it aims to answer are: * Is it feasible to adapt and implement the Fabla-diabetesMM audio diary mobile app among 30 older adults with diabetes and multimorbidity * Does the use of the audio diary mobile app affect self-management outcomes

Eligibility Criteria

Inclusion Criteria: * Diagnosed type 1 or 2 diabetes and at least one comorbidity (eg, obesity, HIV, heart failure, polycystic ovary syndrome, obstructive sleep apnea, and prediabetes with and without hypertension) * Being able to fill in the Redcap surveys, and install and use the audio diary app. Exclusion Criteria: •Those who cannot use (e.g., no mobile phone, incompatible system), read, type, speak, or understand English in Redcap or the audio diary mobile app.

Contact & Investigator

Central Contact

Wenhui Zhang, PhD

✉ wenhui.zhang@emory.edu

📞 762-499-0411

Principal Investigator

Wenhui Zhang, PhD

PRINCIPAL INVESTIGATOR

Emory University

Frequently Asked Questions

Who can join the NCT07474376 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07474376 currently recruiting?

Yes, NCT07474376 is actively recruiting participants. Contact the research team at wenhui.zhang@emory.edu for enrollment information.

Where is the NCT07474376 trial being conducted?

This trial is being conducted at Atlanta, United States.

Who is sponsoring the NCT07474376 clinical trial?

NCT07474376 is sponsored by Emory University. The principal investigator is Wenhui Zhang, PhD at Emory University. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology